González MT, Santos GH, Díaz MC, Selis PDL, Cruz CY, Nazario DM, Jiménez GJJ, Corrales OD

Language: Spanish
References: 13
Page: 33-37
PDF size: 0. Kb.

ABSTRACT

Castleman’s disease is a very rare non-neoplastic lymphoproliferative disorder of unknown cause that is diagnosed on a pathological basis. It is diagnosed microscopically by lymphadenopathy with angiofollicular hyperplasia and plasma cell infiltration with two histologic and clinical patterns well differenciated: The hyaline vascular variant, is usually unicentric and clinically presents as a mediastinal or mesenteric mass and it is surgically curable in the majority of cases.
The other plasma cell variant is commonly multicentric and clinically presents with systemic symptoms and laboratory findings of inflammatory activity, is more aggressive and requires systemic therapy. The Kaposi sarcoma-associated herpesvirus, also called human herpesvirus type 8 and the dysregulated production of human interleukin 6 (IL-6) has been considered as a pivotal factor in the pathogenesis of the disease. It is presented a case that illustrates the unicentric and benignal form of this illness. Besides this article does a revision of theme.

REFERENCES

1. Castleman B, Towne VW. Case records of Massachusetts General Hospital. Case 40011. N Engl J Med 1954;250:26-30.

2. Castleman B, Iverson L, Menéndez VP. Localized mediastinal lymph node hyperplasia resembling thymoma. Cancer 1956;9:822-830.

3. Flendrig JA, Schillings PHM. Benign giant lymphoma: the clinical signs and symptoms. Folia Med Neerl 1969;12:119-120.

4. Guzmán-Fernández MR, Campoy-García F, Pereiro-Sánchez M, Sastre-Moral JL. Espectro clínico de la Enfermedad de Castleman. Galicia Clin 2014; 75 (4): 191-194

5. Katsume A, Saito H, Yamada Y et al. Anti-interleukine 6 (IL-6) receptor antibody supresses Castleman´s disease like symptoms emerged im IL-6 transgenic mice. Cytokine 2002; 20: 304-311.

6. El-Osta H, Kurzrock R. Castleman´s disease from basics mechanisms to molecular therapeutics. The Oncologist 2011; 16: 497-511.

7. Sullivans RJ, Patanowitz L, Casper C et al. HIV/AIDS: Epidemiology, pathophysiology and treatment of Kaposi sarcoma asociated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma and multicentric Castleman`s disease. Clin infect dis 2008; 47: 1209-1215.

8. Aster JC, Brown JR. Catleman´s disease. Uptodate 2013.

9. Talat N, Belgaumkar A. Surgery in Castleman`s disease: A systematic review of 404 published cases. Annals of surgery. 255; 4: 677-684.

10. Accioli F, Chiquetto V, Viani G et al. Radiation therapy in the treatment of unicentric Castleman`s disease. J Bras Pneumol. 2013; 39: 116-118.

11. Gerard L, Michot J, Burcheri S et al. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. Blood 2012; 119: 2228-2233.

12. Van Rhee F, Voorhees P et al. Siltuximab, a nobel anti-interleukin 6 monoclonal antibody for Castleman`s disease. J Clin Oncol 2010; 28: 3701-3708.

13. Talat N , Schulte KM. Castleman´s disease: systematic analysis of 416 patients from the literatura. Oncologist 2011; 16: 1316-1324.